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Abstract
Background: Although intra-articular hyaluronic acid is well established as a treatment for osteoarthritis of the
knee, its use in hip osteoarthritis is not based on large randomized controlled trials. There is a need for more
rigorously designed studies on hip osteoarthritis treatment as this subject is still very much under debate.
Methods/Design: Randomized, controlled trial with a three-armed, parallel-group design. Approximately 315
patients complying with the inclusion and exclusion criteria will be randomized into one of the following
treatment groups: infiltration of the hip joint with hyaluronic acid, with a corticosteroid or with 0.125%
bupivacaine.
The following outcome measure instruments will be assessed at baseline, i.e. before the intra-articular injection of
one of the study products, and then again at six weeks, 3 and 6 months after the initial injection: Pain (100 mm
VAS), Harris Hip Score and HOOS, patient assessment of their clinical status (worse, stable or better then at the
time of enrollment) and intake of pain rescue medication (number per week). In addition patients will be asked if
they have complications/adverse events. The six-month follow-up period for all patients will begin on the date the
first injection is administered.
Discussion: This randomized, controlled, three-arm study will hopefully provide robust information on two of the
intra-articular treatments used in hip osteoarthritis, in comparison to bupivacaine.
Trial registration: NCT01079455
Background
Socioeconomic costs have, in general, escalated dramati-
cally in the last ten years [1] with osteoarthritis (OA)
being one of the most important causes for this
increase. OA is a very common problem in the older
population [2,3] and affects almost 5% of people over
65 years of age [4]. OA of the hip is one of the most
common causes of functional impairment in the elderly
[5,6]. Despite the immense impact of this disease on
many people very few effective, non-surgical options are
available to handle it. In this regard, (intra-articular)
pharmacological treatment is of special interest for two
reasons: on the one hand, as basic agent for the relief of
pain and pain flares in more acute situations, and on
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any medium, provided the original work is properly cited.the other, as a way to postpone any surgical intervention
by improving the patients’ subjective quality of life. In
contrast to the knee, the access to the intra-articular
compartment of the hip is rather difficult as a result of
which injection therapy for hip OA has not been com-
monly used in the past.
Nowadays, two generally accepted products are used
for intra-articular injection in the hip: corticosteroids
(CS) and hyaluronic acid (HA). The effects of CS in hip
OA have been demonstrated in several controlled stu-
dies [7,8]. However its widespread use remains contro-
versial because of its short-term effect and reports of
adverse effects following injection [8,9].
The effect of intra-articular HA in the treatment of
hip OA has not been fully elucidated. Although studies
have shown that HA injections provide prolonged relief
from symptoms in patients with knee OA [10-12], some
controversy exists over the benefit of HA in the treat-
ment of hip OA. The conclusion of a literature review
highlighted the absence of placebo-controlled studies in
the treatment of hip OA with intra-articular HA or its
derivatives [13]. This means that the role of intra-articu-
lar HA in the symptomatic treatment of hip OA cannot
be determined conclusively. Nevertheless published data
suggest that intra-articular injections of HA in hip OA
may be effective. Another literature review showed a
relatively low level of evidence of the included studies,
although the authors concluded that intra-articular
injection of HA, performed under fluoroscopic or ultra-
sound guidance seems to be an effective treatment and
may be an alternative treatment of hip OA [14]. Dou-
ble-blind, controlled studies with a higher level of evi-
dence are required to confirm these data.
The effectiveness of HA in comparison to CS is also
not very clear. One study compared the results of HA
with that of CS in patients with hip OA, but a higher
number of patients was needed to clarify their conclu-
sion [15]. Most published studies do not have a reliable
control group, have too short follow-up periods, or a
bias in outcome measure [16,17].
The aim of our randomized, controlled study is to
compare the effects of intra-articular injections of HA
and CS with a control group, which will receive an
intra-articular infiltration with bupivacaine, in patients
with painful hip OA. To our knowledge there are no
clinical studies which compare the effects of HA, CS
and bupivacaine in patients with hip OA.
Hypothesis
(1) There are differences in functional outcome [differ-
ences of more than 10 points using the Harris Hip
Score (HHS): [18]] and the Visual Analog Score [VAS:
difference of more than 10 mm [19]] between the treat-
ment groups (HA and CS infiltration) and the control
group (Bupivacaine) in favour of the treatment groups,
at 6 months follow-up in the treatment of symptomatic
hip OA patients.
(2) There are differences in secondary outcome mea-
sures [Hip disability and Osteoarthritis Outcome Score
(HOOS) [20]] between the treatment groups and the
control group in favour of the treatment groups, at 6
weeks, 3 and 6 months follow-up in the treatment of
symptomatic hip OA patients.
(3) There are differences in functional outcome and
the VAS between the treatment groups and the control
group in favour of the treatment groups, at 6 weeks and
3 months follow-up in the treatment of symptomatic
hip OA patients.
Methods/design
All patients will be evaluated in the outpatient clinic of
our department. After checking the inclusion and
exclusion criteria (table 1), eligible patients will be
informed about the study and the study design. They
will also be well informed about the advantages and
disadvantages of participation and the adverse effects
of the products. They will be given time to decide if
they wish to participate and will be told that their
treatment at the centre would not be jeopardized if
they declined to participate.
Eligible patients that accept to participate will be
asked to sign the informed consent form and will be
assigned an inclusion number. Approximately 1 month
later they will have their treatment (= infiltration).
At day 0 [the day of the infiltration (table 2)] demo-
graphic data including age, height, weight, body-mass
index (BMI), target hip joint, and the use of nonsteroi-
dal anti-inflammatory drugs will be recorded. The type
of treatment the patient will receive will be checked. A
nurse working at our day hospital will check the inclu-
sion number and from the internet site http://www.ran-
domizer.org she will, on the day of infiltration, obtain a
randomized number ranging from 1 to 3 which corre-
sponds to the treatment injection to be given.
Approximately 315 patients will be included in the
study. (see: Planned statistical analysis and sample size
calculation).
Injection of the study drugs will be performed under
sterile conditions by the same experienced orthopaedic
surgeon and senior author (MM) in all patients. After
skin cleaning a lumbar puncture needle is inserted in a
lateral approach. Layer by layer local anaesthesia is per-
formed using lidocaine 1%. Arthrocentesis is carefully
performed prior to each injection to remove any effu-
sion. Iodinated contrast agent Ultravist® (Schering, Ber-
lin, Germany) will be injected. The needle positioning
into the joint cavity will be fluoroscopically controlled
when the contrast is injected. When the needle is in the
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Another option to perform the injection in the hip is
using ultrasound [21,22]. The skin is cleaned and a lum-
bar puncture needle is inserted in an anterior approach.
Layer by layer local anaesthesia is performed using lido-
caine 1%. Arthrocentesis is performed followed by the
injection of the assigned study product. After resting for
2 hours, the patient is allowed to walk and to return
home. The patient is advised to rest at home until the
next morning. Oral symptomatic slow acting drugs for
OA (for example glucosamine and chondroitin) are
authorized if they are taken at a stable dose for more
than 3 months prior to inclusion in the study. These
drugs are continued at a stable dose during the study
treatment period.
There will be 3 different groups of treatment:
1. Infiltration of the hip joint with Hyaluronic Acid
(Ostenil plus 40 mg/2ml).
2. Infiltration of the hip joint with Corticosteroids
(Depo-Medrol 80 mg/2ml).
3. Infiltration of the hip joint with 0.125% Bupiva-
caine (0.125% Marcaine 2 ml).
All the products used in this study are already used in
our department. To date, we have never had problems
using these products.
“Post-injection” data collection will be performed by a
person who is blinded to the treatment received by each
patient and who is skilled in the administration of the
study outcome instruments.
There will also be a diary to be filled in by each
included patient for the first two weeks after the infiltra-
tion to assess if the treatments have an effect on hip
OA. The diary will include a VAS scale (0-100 mm) for
each day. Patients will be required to fill in their VAS
score and also the number of pain killers used each day.
Side effects will also be reported.
In summary we can conclude that both the patient
and the person who will collect the “post-injection” data
will not know which kind of infiltration the patient has
received.
The findings on the initial radiographs will be graded
by a musculoskeletal radiologist, experienced in review-
ing orthopedic X-rays using the Kellgren and Lawrence
grades.
Further information on the study products
Hyaluronic acid
One of the non-operative options used for reducing pain
and maintaining hip mobility in patients with hip OA is
viscosupplementation. Viscosupplementation is the
administration of HA preparations into the affected
joint to supplement the viscoelasticity of the diseased
synovial fluid.
The underlying mechanisms of action of HA in
osteoarthritic joints are not completely understood.
There is increasing evidence to indicate that clinical
Table 1 Eligibility criteria
Inclusion criteria:
1. male and female patients aged between 30 and 70 years
2. pain (VAS) of at least 30 mm on the day of inclusion.
3. radiographic evidence of OA of the hip (Kellgren-Lawrence grading scale 1-3),
4. chronic pain for at least 3 months prior to study entry (day 0),
5. dissatisfaction with previous attempts at non-operative management including nonsteroidal anti-inflammatory drugs.
Exclusion criteria:
1. Kellgren and Lawrence grade 4,
2. an intra-articular hip injection (with any corticosteroid, hyaluronic acid preparation or other) within the previous three months,
3. rapid destructive hip OA.
4. a history of crystalline arthropathy or inflammatory arthritis, neuropathic arthropathy,
5. current other problem in the affected extremity,
6. allergy or hypersensitivity to any of the study medications or to contrast solutions.
Table 2 Flowchart
Day ?? Day of inclusion: Demographic data, clinical history, concomitant medication, informed consent, inclusion/exclusion criteria.
Day 0 Day of infiltration: Pain (VAS), HOOS and HHS-score, randomization and infiltration.
Day 1-14 Diary: Daily VAS and use of pain killers per day.
Week 6 Second consultation: VAS, HOOS and HHS-score.
Week 12 Third consultation: VAS, HOOS and HHS-score.
Week 26 Fourth consultation: VAS, HOOS and HHS-score, end follow-up.
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inflammatory effects, anti-nociceptive effects, normaliza-
tion of endogenous HA synthesis and chondroprotection
[23].
It takes less than a day to clear the injected HA from
the osteoarthritic joint [24]. To increase the average
intra-articular half-life, TRB Chemedica produced
Ostenil Plus which will be used in our study. Ostenil
Plus has a higher a concentration of hyaluronic acid
(40 mg/2 ml) which is twice as much as previously
used in the product Ostenil. In addition Ostenil Plus
contains 10 mg Mannitol, an antioxidant which pro-
tects hyaluronic acid molecules against free radicals
and inhibits the degradation of HA [25]. Ostenil Plus
is a low molecular weight hyaluronic acid (LMW HA)
(1.6 million Dalton).
One meta-analysis showed no important evidence for
a clinically relevant benefit of a high molecular weight
hyaluronic acid (HMW HA) compared with LMW HA
in patients with OA of the knee [26]. The authors con-
cluded that given the lack of a superior effectiveness of
HMW HA over LMW HA and the increased risk of
local adverse events associated with the first, it is better
to use intra-articular LMW HA in patients with OA of
the knee in clinical research or practice.
There is one study comparing low and high molecular
weight HA following intra-articular administration in
hip OA patients [27]. The authors concluded that both
treatments produced a significant reduction in OA
symptoms but there was no statistically significant dif-
ference between the two groups. This study had a small
patient population (32 hips LMW HA and 24 hips
HMW HA) and they did not use a power calculation to
prove that they included enough patients.
Viscosupplementation, performed with the use of
fluoroscopy or ultrasound guidance, is an effective treat-
ment of hip OA and can be an alternative method to
other conservative treatments or total hip arthroplasty
[14,28,29].
Intra-articular injection of HA or its derivates into the
hip joint is safe and well tolerated. However, local
adverse reactions (hot, painful, swollen joint) were
reported, typically occurring 24-72 hours, and mostly
after injection of HMW HA (Hylan) in the knee [30-33].
Ten to thirty per cent of hip OA patients treated with
intra-articular injections of HA reported adverse effects,
which is slightly higher than in OA of the knee [13].
Some patients experienced transient hip pain after the
infiltration but all of them fully recovered in the follow-
ing days without any treatment or with the use of
NSAIDs. Although a single case of septic arthritis was
reported after multiple intra-articular injections [13],
gout, pseudogout and chondrocalcinosis have not been
reported after hip infiltrations with HA.
Corticosteroids
Due to their anti-inflammatory effects, CS have been
used in the treatment of knee OA for many years. Intra-
articular infiltrations of CS in the hip can also reduce
pain, stiffness and disability. Clinical experience has
shown that CS are very useful for the treatment of
exacerbations of OA, but they do not influence the
underlying process of OA. CS are useful for acute peri-
ods of pain in hip OA but this effect only lasts for some
months [7,8,34]. A significant pain reduction at rest and
during activity was seen at 3 and 12 weeks follow-up.
The range of joint motion increased significantly for all
directions and functionality improved significantly after
the injection of CS [35,36].
It is well known that intra-articular injections of CS
have some side effects, particularly after repeated injec-
tions. These include thinning of the cartilage, a higher
risk of infection and weakening of the ligaments of the
injected joint.
Two doses of CS (40 mg and 80 mg) were used in one
study [34]. At 6 weeks, the benefits of the 40 mg and
80 mg doses in improving pain and stiffness of the hip
were similar. However hip function did not improve
with the 40 mg dose but only with the 80 mg dose [34].
In this study we will use Depomedrol 80 mg/2 ml.
Bupivacaine
Bupivacaine is a member of the amide group in the local
anesthetic family and has a molecular weight of 342.9 g/
mol. Because chondrocyte apoptosis has been implicated
in the development of OA [37], it is important to deter-
mine whether bupivacaine has cytotoxic effects on
articular chondrocytes. Chu et al (2006) showed that in
vitro exposure of bovine articular chondrocytes to 0.5%
bupivacaine was cytotoxic and that in cartilage with an
intact surface bupivacaine caused less cell death [38].
The authors concluded that an intact articular surface
may provide a partial barrier to cytoxicity due to
bupivacaine.
A rabbit shoulder model showed no permanent
impairment of cartilage function 3 months after intra-
articular infusion of bupivacaine [39]. Cartilage metabo-
lism was higher than before indicating a reparative abil-
ity to recover from the damage caused by bupivacaine.
No difference in clinical outcome was seen between
0.5% bupivacaine and placebo [40,41]. After total knee
arthroplasty, the use of bupivacaine reduced pain and
the need for narcotics during the first 24 hours [41].
Microscopic evaluation of human articular chondrocytes
showed more than 95% cell death after exposure to
0.5% bupivacaine for 30 minutes [38]. Chondrocytes
exposed to 0.25% bupivacaine showed a time-dependent
reduction in viability, with longer exposure resulting in
more cellular death that continued even after removal of
bupivacaine. Finally, exposure to 0.125% bupivacaine for
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drocytes in comparison to a saline solution. Thus,
human chondrocytes may tolerate bupivacaine 0.125%.
Large human joints show a peak absorption of bupiva-
caine within the first hour [42,43]. The combination of
systemic absorption and either lavage fluid or effusion is
sufficient to dilute the injected bupivacaine to a concen-
tration of less than 0.125%, which reduces the potential
for chondrotoxity [44]. In this study we will use Mar-
caine (0.125%/2 ml bupivacaine).
Description of methodology
This is a randomized, masked-observer, controlled trial
with three-armed parallel-group design. Patients meeting
the inclusion/exclusion criteria will be randomized to
one of the following treatment groups:
1. Infiltration of the hip joint with Hyaluronic Acid.
2. Infiltration of the hip joint with Corticosteroids.
3. Infiltration of the hip joint with 0.125%
Bupivacaine.
A block randomization scheme, with a block size
equal to 8, will be used for the randomization to avoid
at random imbalances in group size. No stratification
variables are considered in the randomization.
Efficacy parameters will be assessed at baseline and at
the planned follow-up visits at 6 weeks, 3 months and 6
months after the injection.
Planned Statistical Analysis & Sample size calculation
A linear regression model for repeated measures will be
used to compare the evolution of the scores between
the groups. More specifically, a direct likelihood
approach will be adopted using an unstructured covar-
iance matrix for the repeated measures (Molenberghs
and Kenward, 2007, Section 14.4). The approach has the
advantage that less stringent assumptions are made, not
only with respect to the covariance structure, but also to
the mechanism underlying the missing observations.
The approach does not assume that all variances or all
covariances will be equal (as is done in classical
repeated-measures ANOVA or in a mixed model using
only a random subject effect). Furthermore, the
approach allows that the missingness depends on the
observed values (the so-called missing at random
assumption (MAR)), whereas an analysis restricted to
patients with complete information assumes the miss-
ingness to be completely at random (MCAR) (G. Molen-
berghs and M.G. Kenward)[45].
The primary analysis is based on intention-to-treat, i.e.
all patients who received an infiltration at baseline are
included. Appropriate transformations will be consid-
ered if needed to meet the statistical assumptions of the
regression model. Time point-specific comparisons
between the groups of the changes with respect to base-
line will be made based on this model. Confidence inter-
vals (CI) of the change as well as the difference (at each
timepoint) between groups will be constructed. To pro-
tect against an inflated type-I error (due to the presence
of two outcomes and two pairwise comparisons), an
alpha-level of 0.01 will be used for each comparison
with respect to the control group (Bonferroni
correction).
A sample size calculation was performed to have at
least 80% power to detect in both groups compared
with placebo, a clinically meaningful difference in
change (baseline-6 months) of 10 mm in VAS and 10
points in HSS. The SD of HSS and VAS is assumed to
be equal to 16 and 20 respectively. Estimates are
o b t a i n e df r o mF r i h a g e ne ta l .[ 4 6 ]a n dQ v i s t g a a r d[ 1 5 ] .
Assuming a moderate correlation of 0.5 between the
measurement at baseline and after 6 months, a total of
285 patients are needed, i.e., 95 subjects in each group.
With this sample size, 80%power is achieved for VAS
and 96.2% for HHS. The number of included subjects
will be increased by 10% to compensate for the loss of
power due to patients with missing observations (there-
fore, 105 patients per group will be recruited). Interim
analyses are planned after 1/3 and 2/3 of the patients
included reach the end of the follow-up period to allow
for an early stopping of the study (or accrual of patients
in a specific treatment group) due to rejection of the
null hypothesis. Using the O’Brien-Fleming method
(O’Brien and Fleming 1979) results in respectively
|4.495|, |3.178| and |2.595| as critical values for the
Z-statistic at the three analysis time points. Otherwise
stated, p-values are declared significant if they reach
p < 0.000007, p < 0.00148 and p < 0.0095 at the first
interim analysis, the second interim analysis and at the
final analysis, respectively. (Note that the ‘price to pay’
for performing the interim analysis is a slightly more
conservative alpha-level at the final analysis, i.e. alpha =
0.0095 instead of alpha = 0.01)
Primary outcomes
Assessment of group differences at 6 months for:
￿ Harris Hip Score (HHS) [18]: this score will be used
as a self-administered questionnaire in accordance with
the developers’ instructions. The Harris Hip Score was
first developed in 1967 and is accepted as one of the
best used questionnaires dealing with hip function. It is
a disease-specific scoring system which was introduced
to provide an evaluation system for various hip disabil-
ities and methods of treatment. This Score gives a maxi-
mum of 100 points, with domains of pain, function,
deformity and motion. Pain and function are the two
basic considerations and receive the heaviest weighting
(44 and 47 points, respectively). Range of motion and
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fore receive five and four points, respectively. Function
is subdivided into activity of daily living (ADL, 14
points) and gait (33 points).
￿ Visual Analog Score (VAS) [19]: this score is a self-
assessment of variation in pain intensity, measured on a
simple 100-mm-long continuous scale of absolutes ran-
ging from 0 = “no pain” to 100 = “extreme pain”.T h e
percentage of pain is determined by physically measur-
ing from the “0” end to the patients’ mark on the pain
scale and dividing this value by total length of the line.
The advantage of the VAS is that you can determine the
change in pain by taking the difference between any two
recordings of pain severity.
Secondary outcomes
Assessment of group differences on:
￿ Hip disability and Osteoarthritis Outcome Score
(HOOS) [20]: this score will be used as a self-adminis-
tered questionnaire with the help of the developers’
instructions. The HOOS is an adaptation of the Knee
disability and Osteoarthritis Outcome Score (KOOS)
intended to evaluate symptoms and functional limita-
tions related to the hip. The HOOS consists of 40 items
assessing five different patient-relevant groups: Pain (P)
(ten items); Symptoms (S) including stiffness and range
of motion (five items); Activity limitations-daily living
(A) (seventeen items); Sport and Recreation Function
(SP) (four items); and Hip Related Quality of Life (Q)
(four items). The HOOS contains all Western Ontario
and McMaster Universities Osteoarthritis Index
(WOMAC) questions in unchanged form. The
WOMAC scores are often used in scientific literature
and it is important that if needed the WOMAC scores
can be calculated from the HOOS questionnaire. To
answer each question, five options are used (no, mild,
moderate, severe, extreme). All items are scored from
zero to four, and each of the five subscales will be calcu-
lated as the sum of the items included. The HOOS is
transformed into a 0-100 worst to best score.
￿ VAS, Harris Hip Score: at all follow-up time points,
except after 6 months
￿ Patient evaluation of treatment outcome: The
patients will be asked to assess their status on a 3-point
scale (worse, stable or better then at the time of
enrollment).
￿ Intake of escape medication: The number of escape
medication taken/day will be determined.
￿ Safety: All complications/adverse events will be eval-
uated and the relationship to the test product deter-
mined. When they have complications, patients will be
seen in our department earlier than normal.
The above primary and secondary measure instru-
ments will be assessed at the time of enrollment into
the study prior to any injection (baseline), and then
again at six weeks, 3 and 6 months after the injection.
The six-month follow-up period for all patients will
begin on the date the injection is administered.
Ethical review committee and informed consent
requirements
Ethical approval was necessary because this is a prospec-
tive randomized study. Ethical approval has been
obtained from the ethical committee of the Catholic
University, Leuven. Informed consent forms will be
signed by the patients before inclusion into our study. If
patients, after reading the patient information, have any
questions about our study protocol, they can contact Dr.
Sascha Colen or Dr. Michiel Mulier.
Discussion
This study is primarily designed to evaluate the effec-
tiveness of non-operative treatment of hip OA using HA
and CS infiltrations. A comparison is made between
HA, CS and bupivacaine (control group) infiltrations.
There have been studies and even randomized clinical
trials on non-operative treatment of hip OA but the
methodological quality is often poor. There is a need for
more rigorously designed studies on hip OA treatment
as this subject is still very much under debate. By pub-
lishing our protocol we wish to share the robust design
and methodological quality of our protocol. Moreover,
when the design of a study is published it will help to
achieve transparency about why and how studies are
undertaken. The publication of a study design may help
to reduce the problem of publication bias, i.e. selective
publication of positive associations and disregarding
negative and weak associations, prevent unnecessary
duplication of research efforts and duplicate publication.
To our knowledge, there has never been a similar study
design published on the same subject. By making this
study design available we wish to contribute to a more
in-depth research on non-operative treatment of
osteoarthritis of the hip and prevent publication bias for
this double blinded randomized trial. Results of the trial
will be disseminated through publication in relevant
peer-reviewed journals and conference proceedings.
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